AstraZeneca (LON:AZN) Given Buy Rating at Berenberg Bank

AstraZeneca (LON:AZN - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at Berenberg Bank in a research note issued on Monday,Digital Look reports. They currently have a £142 price target on the biopharmaceutical company's stock. Berenberg Bank's price objective suggests a potential upside of 19.89% from the stock's previous close.5 Oversold Stocks to Buy Right NowAZN has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a £110 price target on shares of AstraZeneca in a research note on Wednesday, July 30th. Shore Capital reissued a "buy" rating and issued a £135 price objective on shares of AstraZeneca in a research note on Tuesday, July 29th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of "Moderate Buy" and a consensus price target of £131.75.Check Out Our Latest Report on AstraZenecaAstraZeneca Price Performance20 best healthcare dividend stocks to invest inShares of AZN stock opened at £118.44 on Monday. The stock's fifty day simple moving average is £109.33 and its 200 day simple moving average is £109.16. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The firm has a market cap of £183.61 billion, a price-to-earnings ratio of 2,230.51, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a one year low of GBX 9,573.51 and a one year high of £133.88. Insider Buying and SellingIn other news, insider Aradhana Sarin sold 9,563 shares of the company's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of £115.12, for a total transaction of £1,100,892.56. Corporate insiders own 0.15% of the company's stock. AstraZeneca Company Profile (Get Free Report)3 stocks that crushed earnings estimates and still tankedAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.Further ReadingFive stocks we like better than AstraZeneca3 Defense Stocks Set to Benefit From Increased Military SpendingACM Research: Why This Chinese Chip Stock Is Just Getting StartedEV Stocks and How to Profit from Them Auto Tariffs Are Coming Down: 3 Stocks to Benefit Soon3 Warren Buffett Stocks to Buy NowTencent Music Stock Outshines Spotify as China’s Music GiantThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in AstraZeneca Right Now?Before you consider AstraZeneca, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here